Pilot Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients with IDH2 Mutation
This phase I trial studies the side effects of using enasidenib as maintenance therapy in treating patients with acute myeloid leukemia with IDH2 mutation following donor stem cell transplant. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Primary Objective Evaluate the safety and tolerability of Enasidenib as post HCT maintenance therapy in patients with IDH2+ AML. Secondary Objective Assess overall and leukemia free survival in patients post allogeneic HCT; and Estimate relapse incidence, non-relapse mortality, GVHD and relapse free survival (GRFS) in patients receiving Enasidenib maintenance therapy.
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.